First Look at New CDK 4/6 Data in Metastatic Breast Cancer First Look at New CDK 4/6 Data in Metastatic Breast Cancer

ASCO 2017 featured a number of important studies looking at the role of CDK 4/6 inhibitors in patients with hormone receptor-positive, HER2-negative metastatic breast cancer.Medscape Oncology

Source: Medscape Hematology-Oncology Headlines - June 5, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news